Precipio, Inc. (PRPO) News

Precipio, Inc. (PRPO): $1.16

0.04 (+3.57%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PRPO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 455

in industry

Filter PRPO News Items

PRPO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest PRPO News From Around the Web

Below are the latest news stories about Precipio Inc that investors may wish to consider to help them evaluate PRPO as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

I hope you got your rest out over the holiday weekend because we're starting off Monday with the biggest pre-market stock movers!

William White on InvestorPlace | November 29, 2021

Precipio (PRPO) Receives a Buy from Maxim Group

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Precipio (PRPO – Research Report), with a price target of $7.00. The company's shares closed last Tuesday at $1.85, close to its 52-week low of $1.72. According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -3.4% and a 26.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. Precipio has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.

Brian Anderson on TipRanks | November 23, 2021

New York State Approves Precipio’s HemeScreen for POL clinical use

New York Cancer & Blood POL will commence the use of HemeScreen in its laboratoryNEW HAVEN, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that its HemeScreen RUO assay has received the required approval from New York State’s Department of Health (NY DOH). Hemescreen can now be used by New York based physician-owned laboratories (POLs) who apply to run HemeScreen in their lab as a laboratory-developed test (LDT). New York Sta

Yahoo | November 18, 2021

89bio Announces Appointment of Kathy LaPorte to its Board of Directors

SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry lea

Yahoo | November 3, 2021

Precipio Announces Q3-2021 and year-end Shareholder Update Call

Conference Call to be held on Monday, November 15th, 2021 at 5:00 PM ESTNEW HAVEN, Conn., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2021 update call on Monday, November 15th at 5:00 PM ET. The call will include updates on the company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. confer

Yahoo | November 1, 2021

Precipio (NASDAQ:PRPO) shareholders have endured a 44% loss from investing in the stock three years ago

For many investors, the main point of stock picking is to generate higher returns than the overall market. But if you...

Yahoo | November 1, 2021

American Oncology Network Partners with Precipio to Bring HemeScreen® into AON’s Laboratory

HemeScreen Assays will enable AON to deliver rapid patient diagnostics for hematologic malignancies through advanced molecular screening technologyNEW HAVEN, Conn. and FORT MYERS, Fla., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), and American Oncology Network, LLC (AON), a high-growth community oncology provider, announces the signing of an agreement under which AON will adopt Precipio’s HemeScreen® technology and begin running HemeScreen

Yahoo | August 26, 2021

Precipio Reschedules Q2-2021 Shareholder Update Call

Due to a schedule conflict, the call is moved to Thursday August 26th at 5:00PM ESTNEW HAVEN, Conn., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be rescheduling its Q2-2021 update call from Monday August 23rd to Thursday, August 26th at 5:00 PM ET due to a schedule conflict. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference

Yahoo | August 20, 2021

Precipio Corrects Announcement of Q2-2021 Shareholder Update Call

(Reference to “year-end” was included incorrectly)NEW HAVEN, Conn., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2021 update call on Monday, August 23rd at 5:00 PM ET. The call will include discussions on all of the company’s core businesses. The shareholder communication issued yesterday, August 12th, inadvertently referenced “year-end” in lieu of “Q2-2021 Company Update”. We wish to inform you of this misstatement,

Yahoo | August 13, 2021

Precipio Announces Q2-2021 and year-end Shareholder Update Call

Conference Call to be held on Monday, August 23rd, 2021 at 5:00 PM ESTNEW HAVEN, Conn., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2021 update call on Monday, August 23rd at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. con

Yahoo | August 12, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5675 seconds.